A novel high-dose rate and high throughput x-ray irradiation technology for replacement of isotopic sources in radiobiology applications.

一种新颖的高剂量率和高通量 X 射线辐照技术，用于替代放射生物学应用中的同位素源。

• 批准号: 105715
• 金额: $ 42.77万
• 依托单位: XSTRAHL LIMITED
• 依托单位国家: 英国
• 项目类别: Study
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=105715
• 关键词: novel; dose; rate; throughput; ray

The bulk of radiation studies are carried out by isotopic sources (Co60/Cs137), due to their ability to provide a high irradiation rate. However, such sources have become subject to tightening restrictions due to increasing fears surrounding the health and safety (dangerous to human health), security (stolen samples have the potential to be used as weapons), infrastructure required (costly shielding), disposal (costly processing) and increasing regulatory restrictions around use (US Cesium replacement program-CIRP).X-ray sources have provided an alternative for the last few decades, using X-ray tubes in sealed and protected environments, which can be switched on/off, presenting a safer, easy, environmentally friendly and more secure system. X-ray sources can only currently deliver low/medium dose rates(5-6Gy/min) at low throughput rates and with poor dosimetry control (±10-15%), with larger systems costing \>£500,000 per machine, limiting their effectiveness in replacing isotopic sources and reducing their uptake.Through the use of a proprietary x-ray source arrangement, bespoke mechanical and electric systems and revolutionary analysis and control software, Xstrahl Limited (a UK SME) aims to address the limitations associated with conventional x-ray irradiators delivering a solution that enables:\*High-dose rate for high-energy radiobiology as an alternative for isotopic sources.\*High throughput system allowing large-scale experiments.\*Cost reduction of \>50% on existing high-dose solutions, enabling wider uptake.\*Increased health & safety and security aspects (on/off switch/cannot be used outside apparatus).With market need validated (through one-on-one discussion with existing customers) and building on positive user feedback from an initial PoC trial with two users (Well-known R&D institutes), a programme of Industrial Research is require to further development the initial concept into a MVP prototype for user trials in a relevant environment. With Innovate UK's support and if successful in development, the solution will initially be deployed with a range of radiobiology sectors including cell irradiation, whole-body animal irradiation, Sterile Insect Technique and Viral deactivation, all sector who have been slow to adopt x-ray technology due to its current limitations and where market dominance can be established. Xstrahl's technology has the potential to increase the range of users that have access to such equipment while reducing the risk factor involved with the use of isotopic irradiators. The technology has the potential to be exploited globally as well as across a range of R&D sectors including materials science and blood irradiation.

大部分的辐射研究是由同位素源（钴60/铯137）进行的，因为它们能够提供高辐射率。然而，由于对健康和安全的担忧日益增加，这些来源已受到严格的限制。（危害人体健康），安全（被盗样本有可能被用作武器），需要基础设施（昂贵的屏蔽），处置（昂贵的处理）和使用方面越来越多的监管限制（美国铯替代计划-CIRP）。X射线源在过去几十年中提供了一种替代方案，在密封和受保护的环境中使用X射线管，其可以打开/关闭，提供了一种更安全，更容易，更环保、更安全的系统。X射线源目前只能提供低/中剂量率（5- 6 Gy/min），低通量率，剂量控制差（±10-15%），较大的系统每台机器成本> 500，000英镑，限制了其替代同位素源的有效性并减少了其吸收。通过使用专有的X射线源布置，Xstrahl有限公司（一家英国中小企业）采用定制的机械和电气系统以及革命性的分析和控制软件，旨在解决与传统X射线辐照器相关的局限性，提供一种解决方案，实现：\* 高剂量率的高能放射生物学作为同位素源的替代品。\*高通量系统允许大规模实验。与现有高剂量解决方案相比，成本降低\>50%，从而实现更广泛的应用。\*提高健康、安全和安保方面（开关/不能在设备外部使用）。随着市场需求的验证（通过与现有客户的一对一讨论）以及基于来自两个用户（知名研发机构）的初步试用的积极用户反馈，需要一个工业研究计划将初始概念进一步发展为MVP原型，供相关环境中的用户试用。在Innovate UK的支持下，如果开发成功，该解决方案最初将部署在一系列放射生物学领域，包括细胞辐照，全身动物辐照，无菌昆虫技术和病毒灭活，由于其目前的局限性，所有部门都缓慢采用X射线技术，并且可以建立市场主导地位。Xstrahl的技术有可能增加使用此类设备的用户范围，同时降低使用同位素辐照器的风险因素。该技术有潜力在全球范围内以及包括材料科学和血液辐照在内的一系列研发部门得到利用。